BioCryst Pharmaceuticals, Inc.
BCRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $159 | $163 | $146 | $132 |
| % Growth | -2.4% | 12.2% | 10.6% | – |
| Cost of Goods Sold | $3 | $3 | $5 | $6 |
| Gross Profit | $157 | $161 | $141 | $125 |
| % Margin | 98.4% | 98.3% | 96.9% | 95.3% |
| R&D Expenses | $44 | $43 | $37 | $49 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $83 | $87 | $82 | $80 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $127 | $131 | $120 | $130 |
| Operating Income | $30 | $30 | $21 | -$5 |
| % Margin | 18.6% | 18.2% | 14.6% | -3.4% |
| Other Income/Exp. Net | -$17 | -$23 | -$20 | -$21 |
| Pre-Tax Income | $12 | $6 | $1 | -$26 |
| Tax Expense | -$1 | $1 | $1 | $1 |
| Net Income | $13 | $5 | $0 | -$27 |
| % Margin | 8.1% | 3.1% | 0% | -20.4% |
| EPS | 0.061 | 0.02 | 0 | -0.13 |
| % Growth | 207% | – | 100% | – |
| EPS Diluted | 0.059 | 0.02 | 0 | -0.13 |
| Weighted Avg Shares Out | 210 | 210 | 209 | 207 |
| Weighted Avg Shares Out Dil | 220 | 220 | 215 | 207 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $3 | $3 | $4 |
| Interest Expense | $20 | $22 | $23 | $24 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $32 | $28 | $25 | -$1 |
| % Margin | 20.2% | 17.4% | 16.9% | -0.9% |